08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

ChemoCentryx, GlaxoSmithKline deal

ChemoCentryx said GlaxoSmithKline returned rights to CCX354, a CC chemokine receptor 1 (CCR1) antagonist that has completed Phase II testing for rheumatoid arthritis (RA). Last year, GSK exercised an option under a 2006...
01:17 , Dec 4, 2013 |  BC Extra  |  Company News

GSK returns remaining ChemoCentryx programs

ChemoCentryx Inc. (NASDAQ:CCXI) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined to exercise its option for CCX168, a small molecule complement receptor 5a (C5aR; CD88) inhibitor in the Phase II CLEAR trial for antineutrophil cytoplasmic antibody (ANCA)-associated...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

ChemoCentryx, GlaxoSmithKline deal

ChemoCentryx said GlaxoSmithKline returned all rights to vercirnon. In August, the pharma suspended the Phase III program for the CC chemokine receptor 9 ( CCR9) antagonist after the product missed the primary and secondary...
01:29 , Sep 19, 2013 |  BC Extra  |  Company News

ChemoCentryx regains vercirnon rights from GSK

ChemoCentryx Inc. (NASDAQ:CCXI) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) returned all rights to vercirnon. In August, the pharma suspended the Phase III program for the CC chemokine receptor 9 ( CCR9) antagonist after the product missed...
23:35 , Aug 23, 2013 |  BC Extra  |  Top Story

ChemoCentryx plummets on Phase III miss

ChemoCentryx Inc. (NASDAQ:CCXI) fell $3.37 (29%) to $8.32 on Friday after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said vercirnon ( GSK1605786) missed the primary and secondary endpoints in the Phase III SHIELD-1 trial to treat Crohn's...
07:00 , Jun 13, 2013 |  BC Innovations  |  Strategy

Uprooting CEEDD

Although GlaxoSmithKline plc has quietly shuttered its Center of Excellence for External Drug Discovery (CEEDD), the pharma maintains it is not deprioritizing early program partnerships. Instead, GSK thinks its R&D scientists have adopted the strategies...
07:00 , Nov 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Autoimmune disease; inflammation; rheumatoid arthritis (RA) CC chemokine receptor 1 (CCR1; CD191) In vitro and mouse...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Clinical News

CCX354: Additional Phase II data

Additional data from the double-blind, international Phase II CARAT-2 trial in 160 patients showed that once-daily 200 mg oral CCX354 missed the secondary endpoints of improving ACR50 (30% vs. 20%, p=0.32) and ACR70 response rates...
08:00 , Feb 13, 2012 |  BioCentury  |  Finance

Calculating ChemoCentryx

The experience of ChemoCentryx Inc. provides more evidence that preclinical-stage Verastem Inc.'s bumped up IPO and $202.3 million valuation isn't a measuring stick for biotechs looking to go public. Indeed, investors took a pound of...
08:00 , Jan 9, 2012 |  BC Week In Review  |  Company News

ChemoCentryx, GlaxoSmithKline deal

GlaxoSmithKline exercised an option for exclusive, worldwide rights to develop and commercialize arthritis compound CCX354 from ChemoCentryx. ChemoCentryx will receive a $25 million option fee, and is eligible for milestones and double-digit royalties. CCX354...